bluebird bio, Inc.

Registration Deadline:


A securities class action has been filed in the USDC – MA. against bluebird bio, Inc. (BLUE) (“Blue” or the “Company”), on behalf of all persons and entities that purchased or otherwise acquired Blue common stock between April 24, 2023 and December 8, 2023, both dates inclusive (the “Class Period”).


Blue is a biotechnology company that researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ßthalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.


The Complaint alleges that the Company’s April 4, 2023 announcement provided investors with false and misleading information in order to bolster investor expectations and share prices. Specifically, Defendants created the false impression that:


(1) they could obtain FDA approval for lovo-cel without any box warnings for haematological malignancies;

(2) they would be granted a priority review voucher by the FDA and in turn sell it in order to strengthen their financial position for the lovocel launch;

(3) as a result, the Company had significantly overstated Lyfgenia’s clinical and/or commercial prospects; and

(4) therefore, the Company’s public statements were materially false and misleading at all relevant times, thereby harming investors.


If you purchased Blue common stock during the Class Period and would like to receive more information or join the action, please enter your contact information below for a FREE consultation and click “Submit Your Information”.


About Lowey Dannenberg

Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has previously recovered billions of dollars on behalf of investors.

If you suffered a loss on your investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below.

An attorney will contact you at no cost to provide you information about joining the action and answer your questions. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.